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Abstract
Active immunization with fibrillar β–amyloid peptide (Aβ42) as well as passive transfer of anti-Aβ
antibodies significantly reduces Aβ plaque deposition, neuritic dystrophy, and astrogliosis in the
brain of mutant amyloid precursor protein (APP)-transgenic mice. Although the mechanism(s) of
clearance of Aβ from the brain following active or passive immunization remains to be determined,
it is clear that anti-Aβ antibodies are critical for clearance. DNA immunization provides an attractive
alternative to direct peptide and adjuvant approaches for inducing a humoral response to Aβ. We
constructed a DNA minigene with Aβ fused to mouse interleukin-4 (pAβ42-IL-4) as a molecular
adjuvant to generate anti-Aβ antibodies and enhance the Th2-type of immune responses. Gene gun
immunizations induced primarily IgG1 and IgG2b anti-Aβ antibodies. Fine epitope analysis with
overlapping peptides of the Aβ42 sequence identified the 1–15 region as a dominant B cell epitope.
The DNA minigeneinduced anti-Aβ antibodies bound to Aβ plaques in brain tissue from an
Alzheimer’s disease patient demonstrating functional activity of the antibodies and the potential for
therapeutic efficacy.
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1 Introduction
Alzheimer’s disease (AD) is the most common form of dementia in the elderly and is
characterized by a progressive loss of memory and a general cognitive decline. The
neuropathological features of the disease include neurofibrillary tangles, deposition of β-
amyloid peptides (Aβ40 or Aβ42) in plaques, and neuronal loss in affected brain regions [1].
The Aβ peptides cleaved from the amyloid precursor protein (APP) by the β- and γ-secretases
[2–5] are believed to play a central role in the onset and progression of AD [6]. Recently,
Schenk et al. [7] demonstrated that immunization of APP-transgenic (APP/Tg) mice with
Aβ42 induced the generation of antibodies, which dramatically reduced the deposition of
amyloid plaques and promoted the clearance of plaques from the brain. Other groups have
reported similar observations and have extended these studies by showing that active
immunization protected mice from developing functional memory deficits [8–10].
Remarkably, passive administration of an anti-Aβ monoclonal antibody to APP/Tg mice also
resulted in decreased Aβ levels in the brain, significantly reducing the AD-like neuropathology
[11,12], and reversing memory deficits [13]. These results suggest that the generation of
antibodies against Aβ in humans might provide protection against the onset of AD [14].
Based on these data, Aβ immunotherapy has been moved to the clinical trials. The AN1792
vaccine was comprised of Aβ42 as the antigen and QS21 as the adjuvant. Unfortunately, the
vaccine trial was halted because approximately 5% of the participants receiving the vaccine
developed some degree of meningoencephalitis [14,15]. The failure of this clinical trial is
disappointing; however, this does not mean that other Aβ immunotherapy strategies will not
eventually be successful in treating AD. Because Th1-mediated responses have been
implicated in many autoimmune diseases [16], there has been speculation that the adjuvant
may have contributed to the adverse response in a subset of the patients receiving the AN1792
vaccine [17,18]. Alternative, immunotherapy approaches that polarize the immune response
to Aβ towards a Th2 phenotype, that in some cases have been shown to inhibit autoimmune
diseases, may provide significant advantages [19,20,21]. An example of this type of approach
is the intranasal immunization of APP/Tg mice with Aβ42 but without a conventional adjuvant,
which was shown to induce a Th2-mediated humoral response to Aβ [18,22].
Another adjuvant-free vaccination approach is DNA immunization, which has been shown to
generate potent humoral and cellular immune responses against viral, tumor, and foreign
antigens [23–34]. Importantly, it has also been reported that co-administration of IL-4 cytokine
gene along with a gene, encoding foreign or “self” antigens, caused the immune response to
be driven toward a more Th2-like phenotype [20,21,35–39]. Here we describe a novel chimeric
DNA minigene encoding Aβ fused with mouse IL-4. Immunization of wild-type mice with the
pAβ42-IL-4 generated a potent humoral response to Aβ. Analysis of the IgG isotypes showed
that IgG1 and IgG2b were the predominant species, which suggests that the immune response
was primarily Th2-mediated. The anti-Aβ antibodies generated were specific for the N-
terminal region of Aβ42 and recognized Aβ plaques in human AD brain tissue, which indicated
that antibodies are potentially therapeutic.
2 Results
2.1 Expression of chimeric DNA minigenes in vitro
Three different plasmids were constructed (Fig. 1a, b), and expression of all plasmids has been
confirmed by analyzing the lysate and supernatants of transiently transfected Chinese hamster
ovary (CHO) cells (Fig. 1c–e). The additional bands in the region between 19–24 kDa (lanes
1–2) likely represent different glycosylation states [40] of Aβ42-IL-4 or Aβ28-IL-4 fusion
proteins. Importantly, we did not detect any Aβ peptides in the supernatant or lysate of cells
transfected with vector DNA (Fig. 1c, lane 2, and data not shown). In addition to Western blot
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(WB), the expression of Aβ42, Aβ42-IL-4, and Aβ28-IL-4 were confirmed by flow cytometry
analysis using immunostaining with monoclonal anti-Aβ42 6E10 and anti-IL-4 antibodies (Fig.
1f–h). Transiently transfected CHO cells expressed Aβ42, Aβ42-IL-4 and Aβ28-IL-4 molecules.
2.2 Generation of anti-Aβ antibodies
We immunized B6SJLF1 mice by bombardment of the skin with microscopic gold particles
coated with the various DNA minigenes using the Helios gene gun. Mice immunized with
pAβ42 did not generate anti-Aβ42 antibodies (data not shown). In contrast, conjugation of
Aβ42 with IL-4 resulted in a robust anti-Aβ42 immune response generated by three out of eight
experimental mice after only two boosts. Anti-Aβ42 antibody responses in three mice were
moderate, whereas the remaining two mice responded weakly (Fig. 2a). Antibody titers of the
pooled sera were detected in two separate experiments and were equal to 1:3,200 (Fig. 2b).
Mice immunized with vector did not induce anti-Aβ42 antibody production, whereas injection
of psHA-mC3d3 generated only antihemagglutinin (HA)-specific antibodies (data not shown).
Thus, the presence of the mouse IL-4 molecular adjuvant in the plasmid was critical for
generation of anti-Aβ specific antibody responses.
There is a high level of homology between human and rodent Aβ42 peptides [41]. Accordingly,
we demonstrated that immunization with pAβ42-IL-4 that encodes human Aβ42 induces cross-
reactivity with mouse Aβ42. However, the antisera bound to rodent Aβ42 two times weaker
than to human Aβ42 (data not shown). Because we demonstrated the immune response to the
self-Aβ42 peptide, it was also interesting to analyze antibody production to the self-IL-4
molecule. Our data indicate that DNA vaccination with pAβ42-IL-4 generated low-titer
antibodies to the IL-4 molecular adjuvant (Fig. 3).
2.3 Characterization of anti-Aβ42 antibodies by isotyping
We analyzed isotypes of anti-Aβ42 antibodies in the sera of six mice, which represent high and
moderate responders. All animals generated IgG1 antibodies, whereas the level of IgG2ab was
negligible. The production of IgG1 antibodies is an indirect measure of the relative contribution
of Th2-type cytokines, whereas IgG2a antibodies reflect the contribution of Th1 to the immune
response [32]. Thus our data indicate that pAβ42-IL-4 minigene induces a highly Th2-polarized
response. Four mice with the highest production of IgG1 antibodies also generated significant
levels of IgG2b (Fig. 4). There was no IgE or IgA antibody production detected in immunized
mice (data not shown).
2.4 Mapping of B cell epitopes and binding to human β-amyloid plaques
In order to identify epitopes recognized by antibodies induced after DNA immunization, we
analyzed binding of immune sera to the six overlapping peptides by competition ELISA. Pre-
incubation of sera from high and moderate responders with the full-length Aβ42 peptide resulted
in the most complete inhibition of antibody binding to the adsorbed Aβ42 peptide (82–98%
inhibition). The peptide Aβ1–15 was also effective, inhibiting the binding of antisera by 49–
92%. In addition, Aβ6–20 showed partial inhibition of antibody binding. Notably, a mixture of
Aβ16–30, Aβ21–35 and Aβ26–42 peptides (2.5 μM each) was ineffective (Fig. 5).
To analyze the capability of these antibodies to bind to Aβ plaques in human brain tissue, we
used pooled sera from six immunized mice. This antiserum bound to Aβ plaques on the brain
sections of cortical tissue from a severe AD case (Fig. 6). The antisera were effective at a
dilution of 1:1,000, the endpoint dilution used in these experiments. The pre-immune sera from
these mice did not bind to the Aβ plaques. Notably, Aβ42 peptide abrogated binding of antisera
to the Aβ plaques in human brain tissue (Fig. 6).
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To examine inflammation-related pathology in the brain of animals immunized with DNA
minigene, we conducted immunohistochemical analysis. To identify microglia activation as
well as leukocyte infiltration and accumulation in the brain, we analyzed expression of CD45,
CD11b, CD4, CD8, and CD54 molecules. As shown in Fig. 7, immunostaining in sections
from the frontoparietal cortex revealed no observable differences between wild-type and
immunized mice. CD11b-positive microglial cells exhibited a resting morphology with long
fine processes. Importantly, CD4-positive cells were found within blood vessels but had not
infiltrated into the neuropil.
3 Discussion
The development of a safe and effective vaccine requires a delicate balance between providing
a specific and adequate immune response to provide protection, and reducing or eliminating
unwanted adverse events that may induce excess inflammation or an autoimmune response.
While there are significant safety concerns about Aβ immunotherapy as a possible treatment
for AD, there is also considerable optimism that these hurdles can be overcome with other
vaccination approaches. Alternative strategies have been suggested, such as using different
adjuvants, different routes of immunization and the using molecular adjuvant(s), such as
cytokines in conjunction with Aβ-based vaccine to drive the Th phenotype toward the desired
pathway [18,19,22,42]. In this study we have employed a chimeric DNA minigene to deliver
a fusion protein containing Aβ antigen together with IL-4 as a molecular adjuvant to amplify
immune response to Aβ and to further polarize the response toward a Th2 phenotype in vivo.
Thirteen years ago, it was demonstrated that a gene could be transferred in situ by inoculation
of a plasmid vector into muscle [43]. Now, the generation of potent humoral and cellular
immune responses to a broad spectrum of pathogen antigens has been demonstrated in different
animal model systems using DNA vaccination [25–30,34,44–49]. DNA immunization offers
significant advantages over peptide/protein-based immunization. First it offers the capability
to modify genes encoding desired antigen(s), to change the cellular localization of an antigen
by adding or removing signal sequences or transmembrane domains, and to target the desired
type of immune response using the appropriate molecular adjuvants. Previously we used these
approaches to generate potent humoral and cellular immune responses against different
antigens [25–28,45,50]. Now to generate potent antibody production to Aβ antigen we prepared
plasmids, encoding antigen (Aβ42 or Aβ28) fused with IL-4 (Fig. 1). We demonstrated that
mice immunized with pAβ42 did not generate anti-Aβ42 antibodies even after six boosts (data
not shown), whereas plasmids, encoding immunogen and IL-4 induced anti-Aβ42 antibodies
after just two boosts (Fig. 2).
We and others have previously mapped B cell epitopes using antisera from mice immunized
with fibrillar Aβ42 and small peptides derived from Aβ42 [11,19,22,51,52]. These results have
been confirmed and the linear Aβ42 epitope spanning residues 4–10 was identified using high-
resolution mass-spectrometry technique [53]. In this report we demonstrated that antibodies
generated after pAβ42-IL-4 immunization also recognized Aβ1–15 peptide. Binding to peptide
Aβ6–20 was detectable, but significantly weaker than binding to Aβ1–15 and Aβ42 (Fig. 5).
Thus, like fibrillar Aβ42 formulated in different adjuvants [11,19,22,51–54], DNA
immunization induced antibodies against linear epitope(s) of Aβ42 that span the N-terminal
amino acids of this peptide. Collectively these data suggest that Aβ1–15 represents the major
B cell antigenic determinant of Aβ42 regardless of DNA or protein immunizations.
Interestingly, binding of antibodies to this region of Aβ42 coincides with the ability of
antibodies to bind native plaques in brain tissue [11,53] and trigger ex vivo phagocytosis
[54]. Antibodies generated after gene gun immunization with pAβ42-IL-4 also recognize
human Aβ plaques in cortical tissues from a severe AD case (Fig. 6).
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Successful DNA immunization with IL-4 as a molecular adjuvant to enhance Th2 type of
immune responses to different immunogens has been previously reported [20,21,35–39].
However, to our knowledge no one examined whether anti-IL-4 antibody production is
generated when IL-4 is used as a fusion protein with the immunogen. In this report we have
demonstrated that mice immunized with pAβ42-IL-4 induced low levels of antibodies to self-
IL-4 cytokine (Fig. 3). Such a response was not unexpected since gene therapy is used to induce
immunological memory against self proinflammatory chemokines [55]. IL-4 cytokine is an
antiinflammatory cytokine with pleiotropic effects on immune cells of multiple lineages. Thus,
production of antibodies to IL-4, unnaturally expressed after DNA vaccination, may be an
important regulatory mechanism that protects an organism from overexpression of this
cytokine.
The antibody isotype has been used as an indirect measure of the contribution of Th1 and Th2
cytokines to the humoral response [56]. We recently demonstrated that B6SJLF1 mice produce
IgG2ab anti-Aβ42 antibodies instead of IgG2a [57]. Accordingly, we analyzed the IgG1 and
IgG2ab profiles of the humoral immune response after DNA immunization. Injections with
pAβ42-IL-4 induced predominantly IgG1 and to a lesser extent IgG2b anti-Aβ42 antibodies.
Anti-Aβ42 antibodies of IgG2ab isotype were negligible (Fig. 4). Thus, the IgG1/ IgG2a ratio
measured following immunization with our chimeric Aβ42-IL-4 minigene implies that a highly
polarized Th2-mediated immune response was generated. More importantly, IgG1 and IgG2b
isotypes of anti-Aβ42 antibodies may correlate with their therapeutic potential [11,13,53,58].
The antibodies generated after Aβ42-IL-4 minigene immunization are predominantly of the
IgG1 isotype and bound to the first 15 amino acids of Aβ42 and to Aβ plaques in the AD brain
tissue. Therefore, DNA immunization with minigene encoding Aβ antigen and IL-4 molecular
adjuvant induces therapeutically potent antibodies to Aβ42.
Because T lymphocyte-mediated meningoencephalitis was observed in some patients after
immunization with Aβ42 [59], we analyzed lymphocyte infiltration into brains of immunized
wild-type mice. Immunohistochemical analysis of brain sections did not reveal
lymphocytemediated neuroinflammation or microglia activation (Fig. 7). Because antibodies
raised against human Aβ42 also recognize rodent Aβ42, and therefore rodent APP, we speculate
that pathological hallmarks in this case may be similar to the ones appearing after vaccination
with self-antigen. Future studies with APP/Tg mice immunized with different pAβ-IL-4
constructs are underway and these experiments will better define the therapeutic effects, such
as reducing the deposition of Aβ plaques, clearance of plaques from the brain, and protection
of mice from developing functional memory deficits, following DNA vaccination.
4 Materials and methods
4.1 Mice
Eight- or ten-week-old female B6SJLF1 mice were purchased from Jackson Laboratories (Bar
Harbor, ME) and housed in the animal facility at the Institute for Brain Aging and Dementia,
University of California, Irvine (UCI), CA. All animals were housed in a temperature- and
light-cyclecontrolled facility and their care was under the guidelines of the National Institutes
of Health and the Institute for Brain Aging and Dementia at UCI.
4.2 DNA constructs
Three different plasmids encoding secreted forms of Aβ peptide were constructed: pAβ42,
encoding Aβ42; pAβ28-IL-4 and pAβ42-IL-4, encoding chimeric proteins, where mouse IL-4
is fused with human Aβ28 or Aβ42, respectively (Fig. 1a, b). The pAβ42 was constructed by
cloning Aβ42 PCR fragment into pVAC (Invivogen, San Diego, CA) expression vector in frame
with IL-2 signal sequence using BamHI and NheI restriction sites. pAβ42-IL-4 and pAβ28-IL-4
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were constructed by fusion of Aβ42 or Aβ28 with IL-4 gene via overlapping PCR techniques
using appropriate primers and then cloning into pVAC expression vector using the same
restriction sites (IL-2 signal sequence was replaced by IL-4 signal sequence). The correct
sequences of the generated plasmids were confirmed by nucleotide sequence analysis. The
structure of plasmid psHA-mC3d3 encoding HA of influenza and three copies of C3d
component of complement was described earlier [28]. All plasmids have been purified by
Endofree plasmid maxi kit (Qiagen, Valencia, CA). Purity of the DNA was confirmed by UV
spectrophotometry (260 nm/280 nm absorbance ratio >1.7) and gel electrophoresis.
4.3 Transfection of cells and expression of Aβ by psAβ42, pAβ28-IL-4 and pAβ42-IL-4
CHO cells (0.8×106) were transiently transfected with 2 μg of the appropriate plasmid
(pAβ42, pAβ42-IL-4, or pAβ28-IL-4) by Lipofectamine Plus Reagent (Invitrogen, Carlsbad,
CA) and expressions of these plasmids were analyzed in the supernatants or lysates of cells.
Cells transfected with vector were used as a negative control. All proteins were detected by
combination of immunoprecipitation (IP) and WB using 6E10 anti-Aβ antibodies (Signet,
MA). Tricine-SDS-polyacrylamide gel (16%, for Aβ42) or 15% Tris-SDS-polyacrylamide gel
(for fusion proteins) were used for electrophoresis. The antibody-antigen complexes were
detected using horseradish peroxidase (HRP)-conjugated anti-mouse antibodies and Luminol
reagent (Santa Cruz Biotechnology, Santa Cruz, CA).
4.4 Flow cytometry
The flow cytometry analysis was used for detection of Aβ42 peptide or Aβ42-IL-4 and Aβ28-
IL-4 fusion proteins in transfected CHO cells. Transiently transfected CHO cells were treated
by inhibitor of intracellular transport brefeldin A (Sigma, St. Louis, MO) at a final
concentration of 5 μg/ml for 16 h. Aβ42 expression was analyzed using monoclonal antibodies
6E10 (0.5 μg per 2.5×105 cells) following staining with FITC-conjugated goat anti-mouse
polyclonal antibodies (BD PharMingen, San Diego, CA). Double staining with both 6E10 and
PE-conjugated anti-mouse IL-4 (0.2 μg per 2.5×105 cells; BD PharMingen) antibodies were
used for analyses of Aβ42-IL-4 and Aβ28-IL-4 expression. Flow cytometry analyses were
performed with a FACScan flow cytometer (Becton Dickinson, Mountain View, CA), and data
were analyzed by CellQuest software (Becton Dickinson).
4.5 Immunization
Immunizations of mice with experimental plasmids (two independent experiments with eight
animals for each plasmid) were performed on shaved abdominal skin using the Helios gene
gun (Bio-Rad, Hercules, CA) as we described [28]. Briefly, mice were bombarded two times
with doses containing 1 μg of DNA per 0.5mg of ~1-μm gold beads (DeGussa-Huls Corp.,
Ridefield Park, NJ) at a helium pressure setting of 400 psi. Mice were immunized and boosted
by the same method biweekly and sera were collected 7–8 days after the final boost. As a
control we used animals (eight in each group) immunized by gene gun bombardment with
psHA-mC3d3 (positive), or with vector (negative) [28].
4.6 ELISA
Total anti-Aβ42 and anti-HA antibodies have been detected as described previously [7,19,28,
57]. Briefly, wells of 96- well plates (Immulon II; Dynatech) were coated with 2.5 μM of human
or mouse Aβ42 in bicarbonate coating buffer (pH 9.7) and incubated 3 h at 37°C or overnight
at 4°C. They were then washed and blocked with 3% non-fat dry milk in Tween-20 Tris buffer
solution (TTBS) for 1–2 h at 37°C. After washing of the wells primary sera from experimental
and control mice were added in duplicate at the indicated dilutions. After incubation (O/N at
4°C) and washing, HRPconjugated anti-mouse IgG was added as recommended by
manufacturer (Jackson Laboratories). Plates were incubated for 1 h at 37°C, washed, and
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freshly prepared OPD substrate solution (o-phenylendiamine in 0.05 M phosphatecitrate
buffer, pH 5.0; Sigma) was added to develop reaction. All plates were analyzed
spectrophotometrically at 405 nm. Anti-HA antibodies have been detected by ELISA exactly
as we described earlier [28]. Anti-IL-4 antibodies were detected as described above except that
plates were coated with 200 pg/ml recombinant mouse IL-4 (BD Phar-Mingen).
4.7 Antibody isotyping
To determine the specific isotypes, sera from individual mice were diluted 1:250 and tested in
duplicate as described above. To detect mouse IgG1, IgG2b, or IgM isotypes, we used anti-
mouse Ig-subclass-specific HRP-conjugated secondary antibodies (Zymed, San Francisco,
CA). To detect mouse IgG2c (IgG2ab) isotype, we used biotin-conjugated mouse anti-mouse
IgG2ab (Igh-1b) monoclonal antibody (PharMingen, San Diego, CA), followed by incubation
with HRP-conjugated streptavidin (Vector Laboratories, Burlingame, CA). For detection of
IgE and IgA isotypes we used appropriate isotype-specific anti-mouse antibodies (Zymed).
4.8 Mapping of Aβ42 antigenic determinants by competition ELISA
Previously, we have detected antigenic determinants in Aβ42 peptide using a competition
ELISA assay where the small overlapping peptides mixed with antisera compete with binding
to the Aβ42-coated plates [19]. Briefly, plates were coated with Aβ42, washed, and blocked, as
described above. Sera from immunized individual mice (diluted 1:250) were mixed with 2.5
μMof Aβ42 peptide or small overlapping peptides spanning amino acids 1–15 (Aβ1–15), 6–20
(Aβ6–20), 11–25 (Aβ11–25), 16–30 (Aβ16–30), 21–35 (Aβ21–35), and 16–42 (Aβ16–42) of Aβ42
and incubated 1 h at 37°C. The peptidetreated sera were added in duplicate to Aβ42-coated
plates and antibody binding was analyzed by ELISA as described above. The percent of
inhibition by small peptides and by control full-length peptide was calculated based on binding
of sera without competing peptides to Aβ42 as 100%.
4.9 Detection of Aβ plaques in human brain tissues
Sera from immunized mice were screened for an ability to bind to Aβ plaques in the human
brain. Briefly, pooled sera were added to the serial 50-μm brain sections of formalinfixed
frontal cortical tissue from a patient (an 80-year-old man with neuropathological and behavioral
patterns typical for severe AD). Sections were pretreated with 90% formic acid, and exogenous
peroxidase was quenched. Three different titers of mice antisera were tested (1:500, 1:750, and
1:1,000 dilutions). As a negative control, we used the same dilutions of pre-immune sera. As
a positive control, monoclonal anti-human Aβ antibody 6E10 (dilution 1:1,500) was used to
immunostain plaques in AD brain sections. Binding of antisera to the plaques was blocked by
soluble Aβ42 peptide in a concentration of 2.5 μM. Binding of antibodies to the brain sections
was determined via VECTASTAIN Elite ABC Mouse IgG /DAB substrate biotin-avidin
system (both kits from Vector Laboratories), according to manufacturer’s recommendations.
Digital camera (Olympus, Japan) was used to view the plaques at 20× image magnification.
4.10 Detection of neuroinflammation in mouse brains
Mice were sacrificed and brains were removed, fixed in 4% paraformaldehyde for 24 h at 4°
C, and subsequently cut in serial 50-μm-thick sections. Sections were pretreated with 0.3%
H2O2 for 30 min to eliminate endogenous peroxidase activity. The following primary
antibodies were used after blocking of sections: CD54 (ICAM) (3E2), CD45 (30-F11), CD11b
(M1/70), CD4 (GK1.5), CD8a (53–6.7) (all from BD PharMingen). All antibodies were
optimally diluted in 0.1 M Tris, 0.1% Triton X-100 and 2% BSA as recommended by the
manufacturer. Bound antibodies were detected using biotinylated anti-hamster (Vector
Laboratories) or preabsorbed biotinylated anti-rat (Jackson Immunoresearch) antibodies
followed by incubation with avidin:biotin peroxidase complex (ABC), using the Vectastain
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Elite kit (Vector Laboratories). Staining reactions were performed with 3,3-diaminobenzidine
(DAB; Sigma) according to manufacturers’ protocols. For negative control, the primary
antibody was omitted from the diluent.
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Fig 1.
(a, b) Schematic representation of the constructs. (a) DNA sequence encoding Aβ42 peptide
was cloned in frame with the IL-2 signal sequence using BamHI and NheI restriction sites; (b)
DNA sequences encoding Aβ42 or Aβ28 peptides fused with IL-4 were generated by PCR and
cloned using BamHI and NheI restriction sites. (c–e) Expression of Aβ42 (c) and Aβ42/28-IL-4
(d, e) minigene cassettes in CHO cells transfected with appropriate plasmid. Protein was
recovered from supernatant or cell lysate by IP and analyzed on 16.5% Tricine-SDS-PAGE
(c) or 15% Tris-SDS-PAGE (d, e) followed by WB. For IP and WB the monoclonal anti-Aβ
antibody 6E10 was used. (c) Lane 1: supernatant of cells transfected with pAβ42; lane 2:
supernatant of cells transfected with vector; lane 3: 5 ng of Aβ42 peptide (HPLC grade, > 95%
purity). (d) Lane 1: lysate of cells transfected with pAβ42-IL-4; lane 2: lysate of cells transfected
with Aβ28-IL-4. (e) Lane 1: supernatant of cells transfected with pAβ42-IL-4; lane 2,
supernatant of cells transfected with pAβ28-IL-4. (f–h) Flow cytometric analysis of the
expression of Aβ42 (f), Aβ42-IL-4 (g) and Aβ28-IL-4 (h) proteins in CHO cells transfected with
appropriate plasmids. Transfected CHO cells were treated with brefeldin A overnight,
incubated with 6E10 antibody alone (f) or 6E10 and rat anti-mouse IL-4-PE (g, h). To detect
Aβ expression, anti-mouse Ig-FITC antibodies were added.
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Fig 2.
Generation of anti-Aβ42 antibodies after gene gun immunization of eight B6SJLF1 mice with
plasmids, encoding Aβ42-IL-4 fusion protein. (a) Serum of each mouse (No. 1–8) was diluted
1:250 and used in ELISA for detection of total Ig (SD represents results from three separate
assays with the same sera). (b) Titer of anti-Aβ42 antibodies was detected in the pooled sera
from immunized mice (SD represent two separate experiments with sera of mice No. 1–4 and
5–8).
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Fig 3.
Titer of anti-IL-4 antibodies detected in the sera of individual mice vaccinated with Aβ42 DNA
immunogen fused with IL-4 molecualr adjuvant (n=8)
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Fig 4.
Isotyping of anti-Aβ42 antibodies after immunization of mice with pAβ42-IL-4. Each serum
from six mice, which represent high and moderate responders (No. 1–4, 6, 7) were diluted
1:250 and used for detection of IgG1, IgG2ab, IgG2b, and IgM subclasses of anti-Aβ42
antibodies. All mice demonstrated IgG1 (Th2)/IgG2ab (Th1) ratio much higher than 1.
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Fig 5.
Mapping of B cell epitopes by six overlapping peptides. Serum from each mouse (No. 1–4, 6,
7) was preincubated with indicated peptides or mixture of peptides before binding to Aβ42-
coated wells. The percent of inhibition by small peptides as well as by control full-length
peptide was calculated based on binding of sera without competing peptides to Aβ42 as 100%.
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Fig 6.
Binding of immune (Aβ42-IL-4), pre-immune (negative control) sera, and 6E10 monoclonal
antibody (positive control) to the 50-μm brain sections of formalin-fixed cortical tissues from
an 80-year-old man with neuropathological and behavioral patterns typical to severe AD. Both
pre-immune and immune sera were used at a dilution of 1:1,000, whereas the monoclonal
antibody 6E10 was used at a dilution of 1:1,500. Binding of antisera to the brain tissue was
blocked by Aβ42 peptide. Arrows indicate senile plaques in frontal cortex sections.
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Fig 7.
Detection of neuroinflammation in brains of mouse immunized with pAβ42-IL-4 or vector.
Markers of neuroinflammation were negative in vaccinated mice compared to control
(immunized with vector) animals. The left column shows sections from the frontoparietal
cortex of a control animal and the right panel from a vaccinated mouse. Markers used are
indicated in each row. No evidence for CD54-, CD45-, or CD8-positive cells was observed.
CD11b-positive microglial cells exhibited a resting morphology with long fine processes
(illustrated in insets). CD4-positive cells were found within blood vessels (insets), but had not
infiltrated into the neuropil. Bars = 50 mm. These data were repeated with two other animals.
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